Researcher

Andrea Giacomelli

University of Milan

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 10, 2026 · JOURNAL ARTICLE

Long‐acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations

British Journal of Clinical Pharmacology

Retrospective single-centre assessment of theoretical eligibility and drug-drug interactions; descriptive analysis without a comparator, control group, or clinical outcome measurement.

PreliminaryCristina Gervasoni Andrea Giacomelli Dario Cattaneo

Reported

Total PWH with cancer enrolled168

ART-experienced participants anal…154

Clinical conditions affecting ora…59/154 (38.3%)

AUG 15, 2026 · JOURNAL ARTICLE

Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study

Eclinicalmedicine

Prospective cohort study with adequate sample size and hard clinical outcomes (CVD, cancer, death), but unadjusted effect is attenuated to borderline significance after adjustment (aHR 1.28, 95% CI 0.98–1.67, p=0.073), limiting definitive causal inference.

PromisingCristina Mussini Cancer Risks and Factors Giuseppe Lapadula

Reported

Sample size11652

Participants with obesity647

Participants without obesity11005